Two reports describe the problem of secondary malignancies in patients with LGL. Bennett and colleagues find that I131 tositumomab (Bexxar) following alkylating agent therapy does not increase the risk of tMDS or tAML, while McLaughlin and colleagues find that this risk is increased following fludarabine-based therapy.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Jun 15 2005|
ASJC Scopus subject areas
- Cell Biology